Selami Kocak Toprak

Selami Kocak Toprak
Ankara University · Department of Hematology

MD

About

198
Publications
16,944
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
550
Citations
Citations since 2017
103 Research Items
462 Citations
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
2017201820192020202120222023020406080100
Additional affiliations
January 2012 - present
Baskent University
January 2010 - present
Ankara University

Publications

Publications (198)
Article
Full-text available
Background: Eltrombopag has an off-label indication for haematopoietic cell transplantation in patients experiencing delayed thrombocyte recovery and/or thrombocytopaenia. Aims: To present our centre's experience of using this agent not only for post- haematopoietic cell transplantation thrombocytopaenia but also for poor graft functioning in th...
Preprint
Full-text available
Introduction and Aim: Generic imatinib formulations are increasingly being used as more affordable alternatives worldwide and a few studies have evaluated the safety and efficacy of these. We have retrospectively analyzed our chronic-phase chronic myeloid leukemia (CP- CML) cohort in terms of first-line treatment with Glivec versus generic imatinib...
Conference Paper
Full-text available
INTRODUCTION: Chronic lymphocytic leukemia (CLL), characterized by the accumulation of mature B cells in blood, bone marrow and lymphoid tissues, is the most common hematological malignancy in western societies. Various markers are used to determine the prognosis of CLL, which has a very heterogeneous clinical course. ZAP70 and CD38 are known to be...
Article
Full-text available
z Amaç: Hematolojik maligniteleri olan hastalarda dirençli patojenler nedeniyle gelişen bakteriyel kan dolaşımı enfeksiyonları, yeni kemoterapötik ajanların ve profilaktik antibiyotiklerin daha çok kullanılması nedeniyle artmaktadır. Bu çalışmada, ampirik antibiyotiklerin doğru uygulanmasına yardımcı olmak ve direnci sınırlamak için hematolojik mal...
Conference Paper
Full-text available
Introduction: Despite intensive prophylactic immunosuppressants graft versus host disease (GvHD) occurs in 30-70% of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Management of GvHD is mainly steroid-based, but due to the poor prognosis, an increasing number of studies are focused on GvHD treatment. Mesenchymal stem...
Article
Full-text available
Myelodysplastic syndromes (MDS) is a heterogeneous group of disorders characterized by increased risk of acute myeloid leukemia transformation and cytopenia. The prognosis of MDS patients can be evaluated with various scoring systems, the most commonly used are IPSS (International Prognostic Scoring System), revised-IPSS, and WPSS (WHO classificati...
Conference Paper
Introduction: Multiple Myeloma (MM) is a highly heterogeneous disease that comprises 10% of hematological malignancies. Although the survival of MM patients has improved over time, most of the patients relapse throughout the disease course. New studies are needed to better elucidate the factors responsible for MM heterogeneity and poor prognosis an...
Conference Paper
Full-text available
INTRODUCTION: Chronic lymphocytic leukemia (CLL) is the most common hematological malignancy in western societies. CLL is a disease characterized by the accumulation of mature B cells, which have clonal proliferation and survive apoptosis, in the blood, bone marrow and lymphoid tissues. Various markers are used to determine the prognosis of CLL, wh...
Article
Full-text available
Allogeneic hematopoietic stem cell transplantation (AHSCT) is a promising strategy for treatment of heavily pretreated mycosis fungoides/Sezary syndrome (MF/SS). Herein, we aimed to evaluate the outcomes of AHSCT for heavily pretreated patients with MF/SS retrospectively. This analysis included consecutive 19 patients with MF/SS who received 20 AHS...
Article
Objective: The benefit of pre-transplant consolidation in patients with acute lymphoblastic leukemia (ALL) who achieved first complete remission (CR1) has not yet been clearly demonstrated. Here, we aimed to investigate the relationship between the treatments received before transplantation and transplant outcome in Ph-ALL patients who underwent my...
Article
Introduction: There has been a significant evolution in the therapeutic landscape of chronic myeloid leukemia (CML) since the introduction of imatinib. The European LeukemiaNet (ELN) recommendations serve as a guide for diagnosis, treatment and monitorization of CML but availability and accessibility of diagnostic tools and medications affect their...
Article
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) treatment has a low response rate and a high risk of infection in allogeneic hematopoietic stem cell transplantation. The standard approach to be applied in this situation is uncertain. This study aims to evaluate the effectiveness and safety of alpha-1-antitrypsin (AAT). In the study, t...
Article
Introduction: High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) may provide survival benefit in patients with non-hodgkin lymphoma (NHL). Retrospective analyses suggest that the benefit of HDT extends to elderly patients with NHL, which is an important finding considering that the median age at diagnosis is 67...
Article
Introduction: A vast majority of multiple myeloma (MM) patients requires subsequent lines of therapy following relapses. The choice of regimen following relapse is influenced by response, tolerance to prior therapies, as well as by disease and patient features. Treatment options are limited for those who develop triple-class refractory disease. In...
Article
Full-text available
Patients with solid malignancies are more vulnerable to SARS-CoV-2 infection than healthy population. The outcome of SARS-CoV-2 infection in highly immunosupressed populations, such as in patients with hematological malignancies is a point of interest.We aimed to analyze the symptoms, complications, intensive care unit (ICU) admission and mortality...
Article
Context The AETHERA trial reported an increased progression-free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high-risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Objective To determine the impact and safety of BV as maintenance after ASCT in real-world patients. Design Patients wit...
Article
Objective: In this retrospective study, we shared our single-center experience aimed to evaluate the efficacy and safety of brentuximab vedotin (BV) treatment in relapsed/refractory (R/R) hodgkin lymphoma (HL) patients. Patients and Methods: Between July 2000 and November 2018 we analyzed a total of 18 R/R HL patients in our hematology clinic. Ther...
Article
Objectives: Therapeutic thrombocytapheresis (TTA), also known as platelet depletion, is used for rapid cytoreduction in symptomatic patients or prophylaxis of high-risk patients with extreme thrombocytosis. In this paper, we present our center’s nearly 20-year experience with TTA. Materials and Methods: The medical registry of Ankara University Fa...
Article
Full-text available
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare X-linked genetic disorder. On the contrary to its name, it is a multisystemic disease and various symptoms other than hemoglobinuria could be occurred. It could be life threatening especially because of thromboembolic events. In the last decade, a terminal complement inhibition with eculizumab app...
Article
The AETHERA trial reported an increased progression‐free survival (PFS) when brentuximab vedotin (BV) was used as maintenance therapy in high‐risk Hodgkin lymphoma (HL) after autologous stem cell transplantation (ASCT). Thus, we aimed to determine the impact and safety of BV as maintenance after ASCT in real‐world patients. Seventy‐five patients wi...
Article
Objectives: Existence of panel reactive antibodies is the limiting step in both solid-organ and hematopoietic stem cell transplantation. There are hypotheses related to panel reactive antibody formation, but there is no knowledge about its formation in acute leukemia at diagnosis and during the chemotherapy period, in which there is a strong myelo...
Article
Objective: The optimal timing of measurable residual disease (MRD) evaluation in acute myeloid leukemia (AML) patients has not been well-defined yet. We aimed to investigate the impact of MRD in pre and post allogeneic hematopoietic stem cell transplantation (AHSCT) periods on prognostic parameters. Materials and methods: Seventy-seven AML patie...
Article
Full-text available
Classical Hodgkin lymphoma (cHL) is considered a curable disease; however, in approximately one-third of the responding patients, the disease relapses following completion of therapy. One of the drugs that have been approved for the treatment of relapsed/refractory cHL is nivolumab, an immune check point inhibitor that shows its effects by blocking...
Article
Full-text available
Objectives:Myelodysplastic syndrome (MDS) is a clonal disease that progresses with cytopenias and has leukemia transformation. Allogeneic Stem Cell Transplantation (ASCT) is a curative treatment in MDS patients. However, to which patient group the ASCT transplant will be applied, the treatments to be given before, and the conditioning regimens appl...
Article
PurposeBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and poor prognostic hematological malignancy. There is still no standard treatment established for BPDCN patients. We aim to summarize the main clinical, biological features and treatment of 9 BPDCN patients.Methods Nine patients with BPDCN who had been diagnosed between July 200...
Article
Introduction: The impact of ABO mismatch on outcomes following allo-HSCT remains controversial. In this study, our aim is to define the effect of ABO mismatch on post-transplant outcomes, engraftment kinetics and complications in a large cohort. Patients and Methods: We retrospectively identified 1000 patients who underwent allo-HSCT from either bo...
Article
Introduction Thyroid dysfunction (TD) is one of the major endocrinopathies shown after allogeneic hematopoietic stem cell transplantation over the long term. The incidence and the risk factors for TD have varied widely. Patients and Methods 259 patients with pre‐transplant normal thyroid function tests who survived at least 1 year after allo‐HSCT...
Article
e20038 Background: Allogeneic hematopoietic stem cell transplantation (AHSCT) is a promising strategy for treatment of advanced-stage mycosis fungoides/Sezary syndrome (MF/SS). In this study, we retrospectively analyzed the outcomes of AHSCT for MF/SS and found that MF/SS appears to be susceptible to graft versus leukemia (GVL) effects. Methods: We...
Article
e19522 Background: Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a well-established treatment modality for patients with Myelofibrosis (MF) and still remains the only potentially curative therapy. The aim of this study was to determine overall outcomes of myelofibrosis patients treated with allo-HSCT in our center. Methods: This...
Article
e19536 Background: Pegylated forms of interferon (PEG-IFN) have a better pharmacologic profile than short-acting interferons, resulting in a more convenient less-frequent schedule of injections, less immunogenicity and possibly less toxicity. Several clinical studies of PEG-IFN-α-2a have reported promising results in patients with essential thrombo...
Article
Full-text available
Objectives:Hairy cell leukemia (HCL) is a rare chronic lymphoid malignancy which develops from mature B cells. The frequency is 2% of all leukemias and diagnosed mostly in middle ages. Patients respond to treatment with purine analogues. In this study, our aim is to present our HCL patients, their demographic features, treatment modalities and resp...
Article
Full-text available
Cytogenetic changes are important for the pathophysiology, risk stratification, treatment and prognosis of the myeloid and lymphoid malignancies. The t(1;19) abnormality which is generally observed in childhood acute lymphoblastic leukemia is rarely found in adult myeloid malignancies. Here, we present a case of acute myeloid leukemia (AML) transfo...
Article
Full-text available
Introduction Several studies have attempted to describe the characteristics associated with Large granular lymphocytosis (LGL) lymphocytosis following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its clinical significance. The aim of current study to define the cumulative incidence of LGL lymphocytosis, to identify association...
Article
Full-text available
Introduction Hemorrhagic cystitis (HC) is a serious and common complication of hematopoietic cell transplantation (HCT) affecting both allogeneic (alloHCT) and haploidentical HCT recipients.The aims of this study were to determine the incidence, risk factors, severity, morbidity pattern and toxicity of treatment, and outcome of HC in recipients of...
Article
Introduction:Generic imatinib formulations are increasingly being used as more affordable alternatives worldwide and a few studies have evaluated the safety and efficacy of these formulations prospectively. We have retrospectively analyzed our CML cohort in terms of first line treatment of Glivec versus generic imatinib. This study aims to evaluate...
Article
Full-text available
Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease which is characterized with complement mediated intravascular hemolysis, bone marrow failure and thrombosis. The prevelance of PNH is estimated 1 to 16 cases per million in USA. X-linked somatic mutation of phosphatidylinositol glycan‐A (PIGA) gene in hematopoetic stem cells...
Article
Introduction: Hemorrhagic cystitis (HC) is a serious and common complication of hematopoietic cell transplantation (HCT) affecting both allogeneic (alloHCT) and haploidentical HCT recipients. Early urinary bleeding after transplant is usually attributed to toxic effects of cyclophosphamide (Cy) or other agents used in the conditioning regimen or fo...
Article
Introduction: Several studies have attempted to describe the characteristics associated with large granular lymphocytosis (LGL) following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and its clinical significance. However the clinical features of LGL lymphocytosis in the allo-HSCT setting is still sparse. The current study represe...
Conference Paper
Full-text available
Introduction: Chronic Lymphocytic Leukemia (CLL) is the most common hematologic malignancy in western populations and has different clinical course, varying from patient to patient. In fact, although many patients were asymptomatic and at an early stage at the time of diagnosis, some of them had an unexpectedly aggressive clinical course. In this r...
Article
Résumé L’insuffisance rénale aiguë ou chronique est une complication fréquente après allogreffe de CSH. L’impact de cette complication est important sur la morbidité et la mortalité. Dans le cadre des ateliers d’harmonisation des pratiques en allogreffe organisés de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) à Li...
Article
e19524 Background: Multiple myeloma (MM) is a plasma cell neoplasia characterized by a diffuse clonal plasma cell infiltration of the bone marrow. Serum lactate dehydrogenase (LDH) is a relevant biomarker in MM and in the era of novel agents, LDH confirmed its negative impact on survival in newly diagnosed setting (Bal et al., presented at ASH2018)...
Article
e19532 Background: High dose melphalan and autologous stem cell transplantation (ASCT) significantly prolong survival for patients with multiple myeloma (MM). The purpose of this study is to assess the effects of hemoglobin (Hgb) and serum creatinine (Crea) values at the time of transplantation on the overall outcome of patients with multiple myelo...
Article
Full-text available
Objective: Iron overload (IO) may adversely affect the success of allogeneic hematopoietic stem cell transplantation (AHSCT). This study aims to investigate the impact of IO indicated by pre-transplant serum ferritin (SF) on AHSCT outcomes for acute leukemia. Patients and Methods: This cross-sectional study included patients underwent AHSCT for acut...
Article
Résumé Les complications hépatobiliaires sont fréquentes dans le contexte de l’allogreffe de cellules souches hématopoïétiques (CSH) et contribuent à la morbidité et la mortalité après greffe. Dans le cadre des ateliers d’harmonisation des pratiques en allogreffe organisés de la Société francophone de greffe de moelle et de thérapie cellulaire (SFG...
Article
Full-text available
Introduction In this study, our aim is to analyse the effect of conditioned with TBI on the outcome of DLI after allo-HSCT. Patients and Methods This retrospective study cohort included 152 patients treated with a total of 250 DLI for relapsed hematological malignancies after allo-HSCT from March 1991 through July 2018. Patients received myeloabla...
Article
Full-text available
Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant and non-malignant hematological diseases.The impact of ABO mismatch on outcome following transplantation remains controversial.In this study, our aim is to define effects of ABO mismatch on engraftment, graft vs host disease, relapse free s...
Article
Full-text available
Z Amaç: Bu çalışmada değişik maligniteleri olan non-Hodgkin lenfoma, Hodgkin lenfoma, akut lenfositer lösemi, akut myelositer lösemi, multipl myelom, kronik myelositer lösemi hastalarında human herpesvirüs-8 (HHV-8) IgM ve IgG pozitiflik oranlarının karşılaştırılması amaçlandı. Gereç ve Yöntem: Çalışmaya 50 maligniteli hasta ile 8 sağlıklı birey ol...
Conference Paper
Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant and non-malignant hematological diseases. The impact of ABO mismatch on outcome following transplantation remains controversial. In this study, our aim is to define effects of ABO mismatch on engraftment, graft vs host disease, relapse fre...
Article
Full-text available
Objective: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare non-malignant clonal disease that occurs as a result of acquired somatic mutation in the PIG-A gene in one or more hematopoietic stem cells. The major findings include complement-associated intravascular hemolysis, thrombosis and cytopenias. Fluorescent labeled inactive toxin aerolysis...
Article
Introduction:Donor lymphocyte infusion (DLI) is one of the therapeutic options for patients with relapsed or refractory hematologic malignancies after allogeneic hematopoietic stem cell transplantation (allo-HSCT). DLI can augment the graft-versus-tumor (GVT) effect; however, it can sometimes induce severe graft-versus-host disease (GVHD) and infec...
Article
Background: High burden of patients with hematological malignancies are diagnosed >65 years old. Since then, geriatric interventions can improve quality of life, compliance to therapy and overall survival. Geriatric screening is the best tool to access patients' prognosis. In this study, our aim is to identify our geriatric patients with different...
Article
Introduction: Mantle cell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma with distinguishes clinical, biologic, and molecular characteristics. The MCL-International Prognostic Index (MIPI) incorporates age, EGOC performance status, normalized LDH level and WBC and has improved discriminatory power. The aim of this retrospective singl...
Article
Introduction:Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) still remains the only established curative approach for the treatment of acute leukemia (AL). HLA-matched sibling or relative donor (MRD) is considered the optimal donor source but when this is not available, a matched unrelated donor (MUD) is considered the best alternati...
Article
Background: Hemorrhagic cystitis (HC) is usually a serious complication in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients. In this study, our aim is to define risk factors and outcomes for patients with HC in allo-HSCT setting. Methods: We retrospectively evaluated 249 allo-HSCTs performed between 2011 and 2016 in our...